NGEN logo

NERVGEN PHARMA CORP

NGENNASDAQ
Earnings Nov 12US Equity
$1.50▲ $0.00 (+0.00%)
Latest quote
🔔
Track NGEN
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 0.0%
7d▲ 5.6%
14d▼ 6.8%
30d▼ 22.1%
ytd—
1y—
🏦Market Cap
$161M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data

Trading Snapshot

Day Range
$1.46 – $1.53
52-Week Range
—
Volume (shares)
81,583.905
Avg Volume (shares)
—
Shares Outstanding
107.6M
Next Earnings
2026-11-12

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
—
Dividend Yield
—
Dilution (1yr)
+2.8%
NGEN logo

NERVGEN PHARMA CORP

NGEN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$25M▲ +0.7% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$19M▲ +15.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
72.3M▲ +2.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$22M▲ +$5M YoY
StockOtter · stockotter.space

About NERVGEN PHARMA CORP

NervGen Pharma Corp. is a biotechnology enterprise currently in its clinical development phase, focused on devising therapeutic solutions for nerve injuries and progressive neurodegenerative diseases. Their innovative approach centers on deactivating the natural biological mechanisms that typically impede the nervous system's ability to repair itself.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

Seeking Alpha·27d ago

NervGen Pharma: The Upside Is Large, But Phase 3 Decides Everything

NervGen Pharma Corp. is executing the Phase 3 RESTORE trial for NVG-291, targeting functional recovery in chronic spinal cord injury. RESTORE is powered to detect a 2.5-point treatment effect, with no interim efficacy an

Seeking Alpha·29d ago

NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript

NervGen Pharma Corp. (NGEN) Discusses Challenges and Advances in Drug and Therapy Trials for Spinal Cord Injury Transcript

GlobeNewsWire·Sep 25

NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments

VANCOUVER, British Columbia, Sept. 25, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)

GlobeNewsWire·Sep 9

NervGen to Host Inaugural R&D Day on September 30, 2026

VANCOUVER, British Columbia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI)

GlobeNewsWire·Aug 13

NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates

VANCOUVER, British Columbia, Aug. 13, 2026 (GLOBE NEWSWIRE) -- NervGen (NASDAQ: NGEN), a late-stage clinical biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) a